New Delhi News

DelveInsight’s “Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Degenerative Disc Disease, historical and forecasted epidemiology as well as the Degenerative Disc Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Degenerative Disc Disease, offering comprehensive insights into the Degenerative Disc Disease revenue trends, prevalence, and treatment landscape. The report delves into key Degenerative Disc Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Degenerative Disc Disease therapies. Additionally, we cover the landscape of Degenerative Disc Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Degenerative Disc Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Degenerative Disc Disease space.

To Know in detail about the Degenerative Disc Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Degenerative Disc Disease Market Forecast

Some of the key facts of the Degenerative Disc Disease Market Report:

• The Degenerative Disc Disease market size was valued at approximately USD 1.2 billion in 2025 and is projected to reach nearly USD 7.2 billion by 2036, reflecting robust growth. The market is expected to expand at a CAGR of approximately 19.04% during the 2026–2036 forecast period, driven by advancements in regenerative therapies, increasing disease prevalence, and rising demand for innovative spine care solutions.

• In June 2026, DiscGenics announced that an independent Data Safety Monitoring Board (DSMB) completed a planned safety review of the Phase III IDCT (rebonuputemcel) trial and recommended continuing the study without any protocol modifications, supporting the therapy’s favorable safety profile and ongoing clinical development.

• In May 2026, Angitia Biopharmaceuticals continued the Phase III clinical development of AGA111 for patients with Degenerative Disc Disease undergoing lumbar interbody fusion surgery, assessing the efficacy of a single local injection delivered into the intervertebral disc space.

• In April 2026, In its R&D presentation, Mesoblast announced that, following positive topline Phase III results and the planned submission of a Biologics License Application (BLA), rexlemestrocel-L for chronic low back pain (CLBP) associated with Degenerative Disc Disease (DDD) could potentially receive U.S. FDA approval by Q2 2028 under the Priority Review pathway. This projected timeline aligns with the company’s strategy to accelerate the regulatory review and commercialization of the therapy.

• In April 2026, BioRestorative Therapies announced a strategic collaboration with renowned dermatologist Dr. David J. Goldberg to lead the clinical evaluation and accelerate multi-channel adoption of its regenerative BioCosmeceutical Platform.

• In April 2026, BioRestorative Therapies entered into a strategic partnership with 203 Creates to develop and commercialize an innovative biocosmeceutical platform.

• In April 2026, DiscGenics initiated new patient recruitment activities for its Phase III IDCT trial and broadened enrollment efforts to include individuals suffering from chronic low back pain related to lumbar Degenerative Disc Disease (DDD).

• In February 2026, BioRestorative Therapies completed patient enrollment in its FDA-authorized Phase II trial of BRTX-100, a stem cell therapy for chronic lumbar disc disease. The study enrolled 99 participants and represents one of the largest cell therapy trials conducted in this indication. BioRestorative also reported a positive Type B meeting with the FDA, during which the agency endorsed the proposed Phase III study design for BRTX-100 and discussed a potential accelerated regulatory pathway.

• In January 2026, ReGelTec Inc., a company advancing a percutaneous hydrogel implant for chronic low back pain associated with degenerative disc disease, announced the publication of a study in Pain Physician. The article reports that its HYDRAFIL System for disc augmentation demonstrated sustained, clinically meaningful reductions in pain and disability scores among patients suffering from degenerative disc disease–related chronic low back pain. The HYDRAFIL System is performed as an outpatient procedure and provides interventional pain specialists and patients with a minimally invasive treatment option aimed at relieving pain and enhancing daily functioning without requiring major surgery.

• In December 2025, Companion Spine, a French-American company specializing in surgeon-driven spinal implant innovations, announced that the U.S. Food and Drug Administration (FDA) has granted approval for its DIAM™ Spinal Stabilization System (P240043). The DIAM™ device becomes the first posterior motion-preserving technology approved in the United States for treating moderate to severe primary low back pain caused by degenerative disc disease (DDD) at a single lumbar level (L2–L5). It is indicated for patients who continue to experience symptoms despite undergoing at least six months of conservative, non-surgical treatment.

• In May 2025, ReGelTec Inc., a medical technology company focused on developing a percutaneous hydrogel implant to treat chronic low back pain resulting from degenerative disc disease, has announced that it has obtained CE Mark approval under the European Union Medical Device Regulation (MDR) for its Class III HYDRAFIL System for disc augmentation. This certification establishes a commercial pathway across Europe for the HYDRAFIL System—an outpatient treatment option that provides interventional pain specialists and patients with a minimally invasive alternative aimed at alleviating pain, enhancing daily function, and potentially avoiding the need for major surgical procedures.

• In April 2025, DiscGenics, Inc., a privately owned, late-stage clinical biopharmaceutical company focused on developing allogeneic, cell-based regenerative therapies for musculoskeletal conditions, announced that its double-blind, peer-reviewed study titled “Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial,” has been recognized as one of the top three most impactful articles published in the International Journal of Spine Surgery (IJSS) in 2024.

• In March 2025, Discure Technologies, a clinical-stage medical device company focused on innovative solutions for degenerative disc disease and other orthopedic conditions, announced its acceptance into the U.S. Food and Drug Administration’s (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP). This inclusion is expected to accelerate patient access to the company’s bioelectronic implant, the Discure System, which was previously granted Breakthrough Device designation by the FDA.

• According to estimates, the United States accounted for the largest share of the Degenerative Disc Disease (DDD) market, reaching approximately USD 900 million in 2025.

• According to DelveInsight’s estimates, the 7MM recorded approximately 28 million diagnosed prevalent cases of Degenerative Disc Disease (DDD) in 2025, with the patient population anticipated to increase steadily throughout the forecast period.

• According to estimates, the United States reported approximately 14 million diagnosed prevalent cases of Degenerative Disc Disease (DDD) in 2025, representing the largest patient population among the major markets.

• Among the EU4 countries, France recorded the highest number of diagnosed prevalent Degenerative Disc Disease (DDD) cases in 2025, followed by Germany, while Spain reported the lowest diagnosed patient population.

• In 2025, Degenerative Disc Disease (DDD) was more prevalent among females than males in the United States, with approximately 7.95 million diagnosed cases compared to 6.28 million in males. By 2036, the diagnosed patient population is projected to increase to nearly 8.93 million among females and 7.06 million among males.

• In the United States, individuals aged 60 years and above accounted for the majority of prevalent Degenerative Disc Disease (DDD) cases in 2025, representing approximately 69.2% of the total patient population, while those younger than 60 years comprised around 30.8% of cases.

• Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others

• Key Degenerative Disc Disease Therapies: SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others

• The Degenerative Disc Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Degenerative Disc Disease pipeline products will significantly revolutionize the Degenerative Disc Disease market dynamics.

Degenerative Disc Disease Overview

Degenerative Disc Disease is a condition in which the intervertebral discs of the spine gradually wear down due to aging, repetitive stress, injury, or other factors. As the discs lose hydration and elasticity, they become less effective at cushioning the vertebrae, which can lead to chronic back or neck pain, stiffness, reduced mobility, and, in some cases, nerve compression causing pain, numbness, or weakness in the arms or legs.

Get a Free sample for the Degenerative Disc Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market

Degenerative Disc Disease Epidemiology

The Degenerative Disc Disease epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Degenerative Disc Disease Epidemiology Segmentation:

The Degenerative Disc Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Diagnosed Prevalence Cases of CLBP

• Diagnosed Prevalence Cases of Specific CLBP

• Diagnosed Prevalence Cases of Degenerative Disc Disease (DDD)

• Severity-specific Cases of Degenerative Disc Disease (DDD)

• Age-specific Cases of Degenerative Disc Disease (DDD)

• Type-specific Cases of Degenerative Disc Disease (DDD)

• Total Treated Cases of Degenerative Disc Disease (DDD)

Download the report to understand which factors are driving Degenerative Disc Disease epidemiology trends @ Degenerative Disc Disease Epidemiology Forecast

Degenerative Disc Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Degenerative Disc Disease market or expected to get launched during the study period. The analysis covers Degenerative Disc Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Degenerative Disc Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Degenerative Disc Disease Therapies and Key Companies

• SB-01: Spine BioPharma, Inc.

• BRTX-100: BioRestorative Therapies

• Rexlemestrocel-L: Mesoblast, Ltd.

• Lorecivivint: Biosplice Therapeutics

• CWT 002: Causeway Therapeutics

• AMG0103: AnGes, Inc.

• IDCT: DiscGenics

• KUR 113: Kuros Biosciences

• BRTX-100: BioRestorative Therapies

• AGA111: Angitia Biopharmaceuticals

Discover more about therapies set to grab major Degenerative Disc Disease market share @ Degenerative Disc Disease Treatment Landscape

Degenerative Disc Disease Market Drivers

• Aging Population: The growing elderly population increases the prevalence of degenerative disc disease (DDD), driving demand for effective treatments.

• Rising Incidence of Spinal Disorders: Increasing cases of chronic back pain, spinal degeneration, and sedentary lifestyles contribute to market growth.

• Advancements in Minimally Invasive Treatments: Innovations in regenerative medicine, biologics, spinal implants, and minimally invasive surgical techniques are expanding treatment options.

• Growing Adoption of Regenerative Therapies: Increased research into stem cell therapies, gene therapies, and tissue-engineering approaches is creating new market opportunities.

• Improved Diagnostic Technologies: Advances in MRI, CT imaging, and AI-assisted diagnostics enable earlier and more accurate diagnosis, supporting timely intervention.

Degenerative Disc Disease Market Barriers

• Lack of Disease-Modifying Therapies: Current treatments primarily focus on symptom management rather than reversing disc degeneration.

• High Cost of Advanced Therapies: Regenerative treatments, biologics, and surgical interventions can be expensive, limiting patient accessibility.

• Diagnostic Complexity: Degenerative disc disease symptoms often overlap with other spinal conditions, leading to delayed or inaccurate diagnosis.

• Variable Clinical Outcomes: Differences in disease severity and patient response can affect treatment efficacy and long-term outcomes.

• Limited Reimbursement for Novel Therapies: Inconsistent reimbursement policies for advanced regenerative treatments may hinder widespread adoption.

Scope of the Degenerative Disc Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others

• Key Degenerative Disc Disease Therapies: SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others

• Degenerative Disc Disease Therapeutic Assessment: Degenerative Disc Disease current marketed and Degenerative Disc Disease emerging therapies

• Degenerative Disc Disease Market Dynamics: Degenerative Disc Disease market drivers and Degenerative Disc Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Degenerative Disc Disease Unmet Needs, KOL’s views, Analyst’s views, Degenerative Disc Disease Market Access and Reimbursement

To know more about Degenerative Disc Disease companies working in the treatment market, visit @ Degenerative Disc Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Degenerative Disc Disease Market Report Introduction

2. Executive Summary for Degenerative Disc Disease

3. SWOT analysis of Degenerative Disc Disease

4. Degenerative Disc Disease Patient Share (%) Overview at a Glance

5. Degenerative Disc Disease Market Overview at a Glance

6. Degenerative Disc Disease Disease Background and Overview

7. Degenerative Disc Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Degenerative Disc Disease

9. Degenerative Disc Disease Current Treatment and Medical Practices

10. Degenerative Disc Disease Unmet Needs

11. Degenerative Disc Disease Emerging Therapies

12. Degenerative Disc Disease Market Outlook

13. Country-Wise Degenerative Disc Disease Market Analysis (2022–2036)

14. Degenerative Disc Disease Market Access and Reimbursement of Therapies

15. Degenerative Disc Disease Market Drivers

16. Degenerative Disc Disease Market Barriers

17. Degenerative Disc Disease Appendix

18. Degenerative Disc Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/